Page last updated: 2024-12-08
l 680833
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
L 680833: potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 196813 |
| CHEMBL ID | 93727 |
| SCHEMBL ID | 7374538 |
| MeSH ID | M0221645 |
Synonyms (16)
| Synonym |
|---|
| CHEMBL93727 , |
| l 680833 |
| {4-[(s)-3,3-diethyl-4-oxo-1-((r)-1-p-tolyl-butylcarbamoyl)-azetidin-2-yloxy]-phenyl}-acetic acid |
| bdbm50286252 |
| 2-[4-[(2s)-3,3-diethyl-1-[[(1r)-1-(4-methylphenyl)butyl]carbamoyl]-4-oxoazetidin-2-yl]oxyphenyl]acetic acid |
| l-680,833 |
| 4-((1-(((-1-(4-methylphenyl)butyl)amino)carbonyl)-3,3-diethyl-4-oxo-2-azetidinyl)oxy)benzeneacetic acid |
| 127063-08-5 |
| benzeneacetic acid, 4-((3,3-diethyl-1-(((1-(4-methylphenyl)butyl)amino)carbonyl)-4-oxo-2-azetidinyl)oxy)-, (s-(r*,s*))- |
| SCHEMBL7374538 |
| AKOS030583550 |
| DTXSID10925775 |
| (4-{[3,3-diethyl-1-(hydroxy{[1-(4-methylphenyl)butyl]imino}methyl)-4-oxoazetidin-2-yl]oxy}phenyl)acetic acid |
| 2-(4-(((s)-3,3-diethyl-4-oxo-1-(((r)-1-(p-tolyl)butyl)carbamoyl)azetidin-2-yl)oxy)phenyl)acetic acid |
| benzeneacetic acid, 4-[[(2s)-3,3-diethyl-1-[[[(1r)-1-(4-methylphenyl)butyl]amino]carbonyl]-4-oxo-2-azetidinyl]oxy]- |
| PD161009 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic studies indicate that after oral dosing L-680,833 is bioavailable in rats and rhesus monkeys." | ( Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase. Brause, K; Chandler, GO; Doherty, JB; Dorn, CP; Finke, PE; Hagmann, WK; Hale, JJ; Kissinger, AL; Shah, SK; Thompson, KR, 1993) | 0.29 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " This oral bioavailability is reflected by the inhibition (i) of tissue damage elicited in hamster lungs by intratracheal instillation of human PMNE and (ii) enzyme released from human PMN stimulated after their transfer into the pleural cavity of mice." | ( Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase. Brause, K; Chandler, GO; Doherty, JB; Dorn, CP; Finke, PE; Hagmann, WK; Hale, JJ; Kissinger, AL; Shah, SK; Thompson, KR, 1993) | 0.29 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic studies indicate that after oral dosing L-680,833 is bioavailable in rats and rhesus monkeys." | ( Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase. Brause, K; Chandler, GO; Doherty, JB; Dorn, CP; Finke, PE; Hagmann, WK; Hale, JJ; Kissinger, AL; Shah, SK; Thompson, KR, 1993) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||